Viome Life Sciences has a comprehensive clinical research program that has already enrolled more than 10,000 study participants in more than 20 chronic disease areas. Our clinical research programs generate accurate clinical and molecular data from people with different conditions and healthy participants. Using artificial intelligence and machine learning we gain a deeper insight into the root causes of chronic diseases. The goals of VLS clinical research programs are to develop:
- Better diagnostic tests that can identify early signs and symptoms of diseases, so we can prevent the disease, instead of managing the symptoms.
- Find new molecular markers of disease.
- Better companion diagnostic tests, which will help identify the best choice of therapy.
- Precision nutritional therapies that include diet and supplements and are solely based on the high-resolution data obtained from each person, and not generic recommendations for everyone.
Despite great strides in Medicine, we still do not understand what causes flares in patients with Ankylosing Spondylitis (AS), also known as Axial Spondyloarthropathy (AxSpA). Therefore, the only therapies available today are meant to slow down the disease, not stop it or help patients heal. Research has shown that our genetics does not define whether we are in remission or having a flare. Instead, studies have shown that our environment may play a stronger role, including evidence that specific combinations of food and gut microorganisms may contribute to the disease and its flares. The goal of this study is to better understand the root causes of AS flares.
V-118/V112 Study: Understanding gut-brain interactions
The gut microbiome has been associated with cognition as well as many different neurological diseases and disorders. This study will seek to better understand the connection between the gut and the brain (the gut-brain axis). This study is currently only available to Viome customers.
V-136 study: Understanding the role of the microbiome in the prediction of diabetes and people's risk of developing diabetes.
The goal of this study is to determine if the microbiome can be predictive of an individual’s risk to developing Type II Diabetes. This study is currently only available to Viome customers.
V-146 Study: Understanding the role of the microbiome in autoimmune diseases
The goal of this study is to better understand the role of the microbiome in autoimmune disease progression and the molecular features that may contribute to disease relapse (flares) and to determine if there are specific microbes found in the microbiome that may contribute to disease activity. This study is currently only available to Viome customers.
V-174 Study: A study of vaginal microbiome compositions and functions
Viome is developing a novel vaginal microbiome test. To better understand what microorganisms are present in vaginal samples, and what they are doing we have launched a study seeking to investigate the vaginal microbiome in a large and diverse population.
V-179 study: Understanding adherence to Viome’s personalized nutrition program and improvements in general wellness.
The goal of this study is to understand how well customers follow their results and recommendations (R&R) to define an adherence score and to determine how adherence to Viome R&R improves general well-being. This study is currently only available to Viome customers.
V-202.3 Covid-19 Wellness Survey: Understand the role of the microbiome in health and wellness during the SARS-CoV-2 outbreak.
The goal of this study is to determine the effects of SARS-CoV-2, the virus that causes COVID-19, on general health and wellness. This brief survey asks questions about ones’ general health, symptoms one may have experienced, and nutritional habits.
V-109 Study: Predicting the glycemic response to food using the Viome Gut Intelligence test
The purpose of the study is to collect and analyze physiological, physical, and molecular data from a diverse population to increase our understanding of how such parameters are associated with postprandial glycemic response.